Several generic drugmakers that will produce versions of Pfizer’s COVID-19 antiviral treatment Paxlovid agreed to sell the medicine in low-income and middle-income countries for $25 a course or less, the Clinton Health Access Initiative (CHAI) said on May 12.
Novavax Inc.’s shares plunged nearly 20 percent in premarket trading on May 10 due to uncertainty over global demand for the company’s COVID-19 vaccine following a slow start to deliveries.
A shareholder proposal calling on Moderna Inc. to study transferring production of COVID-19 vaccines to less-developed countries won 24 percent support from investors on April 28 after the company received a rare endorsement from the World Health Organization.
Johnson & Johnson rescinded the company’s forecast for sales of its COVID-19 vaccine, as hesitancy in low income countries has led to a glut of supply of a shot once hoped to be the inoculation of choice for the developing world.
Thirty five generic drugmakers around the world will make cheap versions of Pfizer Inc.’s highly effective COVID-19 oral antiviral Paxlovid to supply the treatment in 95 poorer countries, the U.N.-backed Medicines Patent Pool (MPP) said on March 17.
Moderna Inc. plans to develop and begin testing vaccines targeting 15 of the world’s most worrisome pathogens by 2025 and will permanently waive the company’s COVID-19 vaccine patents for shots intended for certain low-income and middle-income countries.
Pfizer Inc. is expected to provide around 10 million courses of the company’s highly effective COVID-19 antiviral treatment Paxlovid to low-income and middle-income countries during 2022, according to an official with the Global Fund, a healthcare NGO working to buy the pills from the drugmaker.
The global project to share COVID-19 vaccines is struggling to place more than 300 million doses in the latest sign the problem with vaccinating the world is now more about demand than supply.
Antibodies induced by mRNA COVID-19 vaccines keep improving in quality for at least six months while the immune system continues to “train” its antibody-producing B cells, according to a new study. In other research, dysfunctional red blood cells contribute to the blood vessel injuries common in severe COVID-19, according to laboratory studies that also may suggest a way to treat the problem.
A COVID-19 vaccine that can be produced locally in low-income and middle-income countries is yielding promising results in early clinical trials, researchers say. Other researchers believe that once the body has been “primed” by mRNA vaccines to recognize and attack the coronavirus, a booster containing purified versions of virus’ spike protein that could be given intranasally would have many advantages.